

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

COMP/M.5295 - TEVA / BARR

SECTION 1.2

Description of the concentration

On Friday October 31, the Commission received a notification concerning a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004, by which Teva Pharmaceutical Industries Limited (“Teva”), a company incorporated under the laws of Israel, proposes to acquire sole control of Barr Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware, U.S.A., and its various subsidiaries (collectively “Barr”), within the meaning of Article 3(1)(b) of the Council Regulation.

The business activities of the undertakings are:

- Teva: development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients in the U.S. and internationally.
- Barr: development, production and marketing of generic and proprietary branded pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients in the U.S. and internationally.